FDA
approval
· 2021-02-11
FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)
Summary
The FDA approved a supplemental NDA for BIKTARVY from Gilead Sciences, expanding or updating its labeling and/or indication.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)